Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
46(12), P. 13617 - 13646
Published: Nov. 29, 2024
SIGLEC9
(sialic
acid-binding
Ig-like
lectin
9)
is
a
molecule
thought
to
have
significant
influence
on
the
immune
properties
of
colorectal
cancer
(CRC)
tumor
microenvironment
(TME).
In
our
study,
we
assessed
expression
protein
in
CRC
tissue
and
surgical
margin
tissue.
Using
RT-PCR,
analyzed
mutations
KRAS,
NRAS,
BRAF,
PIK3CA,
AKT
genes.
We
observed
significantly
elevated
compared
control
group.
No
differences
were
depending
genes
or
microsatellite
instability
(MSI)
status.
However,
found
higher
high-grade
tumors
low-grade
was
associated
with
multiple
cytokines,
chemokines,
growth
factors
TME.
These
associations
suggest
potential
as
that
plays
crucial
role
shaping
TME,
well
its
therapeutic
relevance,
particularly
group
tumors.
Frontiers in Cell and Developmental Biology,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 7, 2025
The
advent
of
immune
checkpoint
inhibitors
(ICIs)
in
colorectal
cancer
(CRC)
treatment
marks
a
major
breakthrough.
These
therapies
have
proven
safer
and
more
effective
than
traditional
radiotherapy
targeted
treatments.
Immunotherapies
like
pembrolizumab,
nivolumab,
ipilimumab
pioneered
new
avenues,
potentially
improving
patient
outcomes
quality
life.
Additionally,
advances
immunotherapy
prompted
detailed
research
into
CRC
therapies,
especially
those
integrating
ICIs
with
conventional
treatments,
providing
hope
for
patients
shaping
future
practice.
This
review
delves
the
mechanisms
various
evaluates
their
therapeutic
potential
when
combined
radiotherapy,
chemotherapy,
clinical
settings.
It
also
sheds
light
on
current
application
involving
treatment.
Cells,
Journal Year:
2025,
Volume and Issue:
14(7), P. 530 - 530
Published: April 2, 2025
B7-H3
(CD276),
a
member
of
the
B7
immune
checkpoint
family,
plays
critical
role
in
modulating
responses
and
has
emerged
as
promising
target
cancer
therapy.
It
is
highly
expressed
various
malignancies,
where
it
promotes
tumor
evasion
from
T
cell
surveillance
contributes
to
progression,
metastasis,
therapeutic
resistance,
showing
correlation
with
poor
prognosis
patients.
Although
its
receptors
were
not
fully
identified,
signaling
involves
key
intracellular
pathways,
including
JAK/STAT,
NF-κB,
PI3K/Akt,
MAPK,
driving
processes
crucial
for
supporting
growth
such
proliferation,
invasion,
apoptosis
inhibition.
Beyond
modulation,
influences
metabolism,
angiogenesis,
epithelial-to-mesenchymal
transition,
further
exacerbating
aggressiveness.
The
development
B7-H3-targeting
therapies,
monoclonal
antibodies,
antibody–drug
conjugates,
CAR-T
cells,
offers
avenues
treatment.
This
review
provides
an
up-to-date
summary
B7H3
mechanisms
action,
putative
receptors,
ongoing
clinical
trials
evaluating
therapies
targeting
B7H3,
focusing
on
molecule’s
gastrointestinal
tumors.
Gynecologic Oncology Reports,
Journal Year:
2025,
Volume and Issue:
59, P. 101748 - 101748
Published: April 19, 2025
•Pembrolizumab
achieved
long
term
remission
in
recurrent
high-grade
microsatellite-stable
endometrial
carcinosarcoma.•This
case
challenges
conventional
treatment
paradigms
for
microsatellite
stable
carcinosarcoma.•Insurance
initially
denied
immunotherapy,
highlighting
barriers
to
access
rare
malignancies.•This
demonstrates
the
need
further
investigation
of
immune
checkpoint
inhibitors
aggressive
cancers.•Expanding
immunotherapy
eligibility
could
improve
outcomes
patients
with
limited
options.
Clinical and Translational Science,
Journal Year:
2025,
Volume and Issue:
18(4)
Published: April 1, 2025
ABSTRACT
TIGIT
(T
cell
immunoreceptor
with
immunoglobulin
and
tyrosine‐based
inhibitory
motif
(ITIM)
domain),
Vstm3,
VSIG9,
are
newly
recognized
immunological
checkpoints.
They
prominently
expressed
on
CD4+
CD8+
T
cells,
tumor‐infiltrating
lymphocytes
(TILs),
natural
killer
(NK)
regulatory
cells
(Tregs).
The
(TIGIT)
protein
is
crucial
for
immune
modulation
since
it
diminishes
NK
populations
hinders
activity
in
cancer
patients
experimental
models.
CD155,
the
principal
ligand
of
humans,
has
been
as
a
pivotal
target
immunotherapy
owing
to
its
interaction
TIGIT.
CD155
linked
efficacy
anti‐programmed
death
1
(PD‐1)
therapy,
even
without
expression,
underscoring
importance
checkpoint
suppression.
Anti‐TIGIT
medicines,
either
independently
or
conjunction
anti‐PD‐1
treatments,
have
demonstrated
potential
augmenting
responses
malignancies.
This
review
examines
structural
functional
characteristics
protein,
new
developments
anti‐TIGIT
drugs,
their
prospective
use
immunotherapy.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(9), P. 4194 - 4194
Published: April 28, 2025
Colorectal
cancer
(CRC)
progression
occurs
through
three
stages:
adenoma
(pre-cancerous
lesion),
carcinoma
in
situ
(CIS)
and
adenocarcinoma,
with
tumor
stage
playing
a
pivotal
role
the
prognosis
treatment
outcomes.
Despite
therapeutic
advancements,
lack
of
stage-specific
biomarkers
hinders
development
accurate
diagnostic
tools
effective
strategies.
This
study
aims
to
identify
gene
expression
profiles
key
molecular
mechanisms
CRC
providing
insights
into
alterations
across
disease
progression.
Our
methodological
approach
integrates
use
absolute
set
enrichment
analysis
(absGSEA)
on
formalin-fixed
paraffin-embedded
(FFPE)-derived
transcriptomic
data,
combined
large-scale
clinical
validation
experimental
confirmation.
A
comparative
whole
(RNA-seq)
was
performed
FFPE
samples
including
(n
=
10),
8)
adenocarcinoma
11)
samples.
Using
absGSEA,
we
identified
significant
cellular
pathways
putative
associated
each
Key
findings
were
then
validated
large
independent
patient
cohort
1926),
survival
conducted
from
1336
patients
assess
prognostic
relevance
candidate
biomarkers.
The
differentially
expressed
genes
experimentally
using
real-time
PCR
(RT-qPCR).
Pathway
revealed
that
CIS,
apoptotic
processes
Wnt
signaling
more
prominent
than
samples,
while
transcriptional
co-regulatory
protein
kinase
activity,
which
are
critical
for
growth
metastasis,
significantly
enriched
compared
adenoma.
Additionally,
extracellular
matrix
organization
CIS.
Distinct
signatures
stages
differentiate
between
adenoma,
CIS
adenocarcinoma.
In
ARRB1,
CTBP1
CTBP2
overexpressed,
suggesting
their
involvement
early
tumorigenesis,
whereas
RPS3A
COL4A5
transition
benign
malignant
stage.
COL1A2,
CEBPZ,
MED10
PAWR
advanced
Functional
confirmed
ARRB1
CTBP1/2
development,
COL1A2
CEBPZ
involved
remodeling
regulation,
respectively.
Experimental
RT-qPCR
differential
(ARRB1,
RPS3A,
COL4A5,
MED10)
reinforcing
potential
as
These
provide
foundation
distinguish
biomarkers,
helps
strategies
CRC.
